Invitae News - NVTA

Company Name	Stock Ticker Symbol	Market	Type
Invitae Corporation	NVTA	NYSE	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.00%	0.0891	20:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
				0.0891

more quote information »

Recent News

Date	Time	Source	Heading
3/06/2024	08:31	EDGAR2	Form 8-K - Current report
2/06/2024	17:07	EDGAR2	Form 8-K - Current report
1/30/2024	07:00	PRNUS	Invitae Partners with BridgeBio Pharma to Harness Genetic..
1/29/2024	16:01	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
1/24/2024	16:34	EDGAR2	Form 8-K/A - Current report: [Amend]
1/22/2024	07:05	EDGAR2	Form 8-K - Current report
1/22/2024	07:00	PRNUS	Invitae Completes Sale of Reproductive Health Assets to..
1/18/2024	16:10	EDGAR2	Form 8-K - Current report
12/21/2023	21:20	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/21/2023	21:14	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/14/2023	16:29	EDGAR2	Form 8-K - Current report
12/13/2023	16:07	PRNUS	Invitae Divests Ciitizen Health Data Platform and Implements..
12/11/2023	16:41	EDGAR2	Form 8-K - Current report
11/17/2023	16:48	EDGAR2	Form 8-K - Current report
11/15/2023	16:22	EDGAR2	Form 8-K - Current report
11/14/2023	19:58	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/14/2023	19:55	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
11/08/2023	16:36	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/08/2023	16:05	EDGAR2	Form 8-K - Current report
11/08/2023	16:01	PRNUS	Invitae Reports Third Quarter 2023 Financial Results
11/06/2023	16:00	PRNUS	Invitae Launches Enhanced Chemistry of MRD Test to Better..
11/01/2023	06:59	PRNUS	Invitae to Announce Third Quarter 2023 Financial Results on..
10/25/2023	11:00	PRNUS	Landmark Study Reveals Magnitude of Uncertain Results in..
10/20/2023	18:04	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/19/2023	16:38	EDGAR2	Form 8-K - Current report
10/19/2023	16:30	PRNUS	Invitae Appoints Dr. David Sholehvar as Chief Operating..
10/12/2023	16:15	PRNUS	Rural Hospital System Demonstrates the Clinical Benefits of..
10/10/2023	16:30	PRNUS	Invitae to Present Data at the National Society of Genetic..
10/03/2023	12:07	PRNUS	Invitae's Common Hereditary Cancers Panel Receives FDA..
10/02/2023	21:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/02/2023	20:47	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
9/29/2023	20:00	DJN	FDA Gives Marketing Authorization to Invitae Test for Cancer..
9/27/2023	16:29	EDGAR2	Form 8-K - Current report
9/25/2023	18:17	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/25/2023	16:30	PRNUS	Invitae Announces Appointment of Finance Veteran Ana Schrank..
9/22/2023	17:02	EDGAR2	Form 8-K - Current report
9/22/2023	16:30	PRNUS	Invitae Receives Notice of Non-Compliance with NYSE Minimum..
9/14/2023	17:21	EDGAR2	Form 3 - Initial statement of beneficial ownership of..
8/28/2023	16:02	PRNUS	Invitae Hires Industry Veteran Robert Guigley as Chief..
8/23/2023	08:12	EDGAR2	Form 8-K - Current report
8/15/2023	07:30	PRNUS	Clinical Trial Results Support Genetic Testing of All..
8/14/2023	16:02	PRNUS	Invitae Announces Selection of Finance Executive Robert..
8/10/2023	16:03	EDGAR2	Form 424B2 - Prospectus [Rule 424(b)(2)]
8/10/2023	16:01	EDGAR2	Form 424B2 - Prospectus [Rule 424(b)(2)]
8/10/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
8/09/2023	09:22	EDGAR2	Form POS AM - Post-Effective amendments for registration..
8/09/2023	09:20	EDGAR2	Form POS AM - Post-Effective amendments for registration..
8/08/2023	16:40	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/08/2023	16:09	EDGAR2	Form 8-K - Current report
8/08/2023	16:01	PRNUS	Invitae Reports Second Quarter 2023 Financial Results